drugset

drugset / Trial / NCT07377838

Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

NCT07377838 ↗

Phase 3 Not yet recruiting 286 enrolled EHL Bio Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Study of ADSTEM Injection for Patients with Moderate to Severe Subacute and Chronic Atopic Dermatitis

Timeline

Start: 2026-06
Primary completion: 2029-06
Completion: 2029-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ADSTEM	Unknown	1e+08 cells	—

Indications